Atea Pharmaceuticals, Inc. (AVIR): Cash & Equivalents
$95.71M
As of 2025-12-31
$76.55M
As of 2026-06-30
-20.2%
3-year compound annual growth
-35.4%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $95.71M | +47.9% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $64.70M | -55.0% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $143.82M | -23.7% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $188.46M | -75.3% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $764.38M | -10.1% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $850.12M | n/m | 2023-02-28, Balance as of period end |
| 2019-12-31 | $21.66M | -37.2% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $34.49M | n/a | 2021-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | 2025-12-31 | $95.71M | +47.9% |
| LB Pharmaceuticals Inc (LBRX) | 2025-12-31 | $250.17M | +988.8% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $261.34M | +4.2% |
| Omeros Corp (OMER) | 2025-12-31 | $9.66M | +184.1% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $58.45M | +54.7% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $307.53M | -34.8% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $41.32M | -18.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $190.68M | +8.0% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $77.56M | -52.6% |
Compare AVIR, LBRX, ADCT, OMER side by side · Screen every company in Pharmaceutical Preparations ↗